Short Interest in Nanovibronix, Inc. (NASDAQ:NAOV) Rises By 209.9%

Nanovibronix, Inc. (NASDAQ:NAOV) was the target of a large growth in short interest in September. As of September 15th, there was short interest totaling 47,100 shares, a growth of 209.9% from the August 31st total of 15,200 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 5.5% of the company’s stock are sold short. Approximately 5.5% of the company’s stock are sold short. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is currently 0.0 days.

Nanovibronix Trading Down 1.0%

NAOV stock opened at $6.14 on Friday. The stock has a market cap of $4.91 million, a P/E ratio of -0.45 and a beta of 2.17. Nanovibronix has a twelve month low of $4.71 and a twelve month high of $162.50. The company’s 50 day moving average is $6.68 and its two-hundred day moving average is $20.34.

Nanovibronix (NASDAQ:NAOV) last posted its earnings results on Tuesday, August 19th. The company reported ($1.03) EPS for the quarter. Nanovibronix had a negative net margin of 380.29% and a negative return on equity of 45.24%. The company had revenue of $0.49 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research note on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

About Nanovibronix

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.